| 0.2876 0.004 (1.34%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.37 | 1-year : | 0.43 |
| Resists | First : | 0.31 | Second : | 0.37 |
| Pivot price | 0.25 |
|||
| Supports | First : | 0.25 | Second : | 0.21 |
| MAs | MA(5) : | 0.28 |
MA(20) : | 0.24 |
| MA(100) : | 0.5 |
MA(250) : | 1.72 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70 |
D(3) : | 72.9 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 5.13 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VTGN ] has closed below upper band by 14.9%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.27 - 0.27 | 0.27 - 0.28 |
| Close: | 0.28 - 0.28 | 0.28 - 0.29 |
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Thu, 06 Aug 2026
VistaGen Granted Nasdaq Extension to Regain Bid Compliance - theglobeandmail.com
Thu, 06 Aug 2026
Vistagen's second fasedienol dose showed no new safety findings - Stock Titan
Wed, 05 Aug 2026
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Wed, 05 Aug 2026
Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension - Stock Titan
Tue, 04 Aug 2026
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics - Benzinga
Tue, 04 Aug 2026
Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTG - The National Law Review
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 3.504e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 1,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.193e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 595 % |
| Return on Equity (ttm) | -67.9 % |
| Qtrly Rev. Growth | 1.27e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -328.98 |
| EBITDA (p.s.) | 3.175e+006 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.12 |
| Dividend | 0 |
| Forward Dividend | 1.6e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|